Navigation Links
Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Date:5/12/2008

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.

Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A

In the symposium, "Innovations in Emphysema Treatment: Lung Volume Reduction and Lung Volume Reduction Surgery," Zephyr related presentations include:

-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the

principal investigator of VENT, will present on the Durability of

Endobronchial Valve Effect on Lung Function at 6 and 12 Months.

-- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles,

the principal investigator of the VENT radiology core lab, will

present on Fissure Integrity As a Marker of Collateral Ventilation

Across Lung Lobes.

-- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will

present on the Treatment of Advanced Emphysema by Endoscopic Volume

Reduction.

-- John Travaline, M.D., Temple University, will present on the Efficacy

of Endobronchial Valves in the Treatment of Persistent Air Leaks.

Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A

-- Charlie Strange, M.D., Medical University of South Carolina will

present on the relation of FEV1/FVC and Fissure Integrity in the VENT

Study.

Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G

-- Frank Sciurba, M.D., will present on Bronchoscopic Methods for

Palliation of Emphysema.

About the Zephyr Endobronchial Valve

The Zephyr EBV is a novel, minimally-invasive device intended to treat emphysema. The Zephyr EBV is designed to isolate diseased, overinflated portions of the lung and cause them to shrink thereby allowing healthier portions of the lung to function more normally.

The Zephyr EBV is CE marked and is commercially available in Europe and other international markets, including Australia, New Zealand, Hong Kong and Singapore. The Zephyr EBV is limited to investigational use in the United States. The company's Premarket Approval Application is currently under review by the U.S. Food and Drug Administration.

About Emphasys Medical

Emphasys Medical (http://www.emphasysmedical.com) is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Based in Redwood City, California, Emphasys Medical was incubated at The Foundry.


'/>"/>
SOURCE Emphasys Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy
2. MSU engineering team designs innovative medical device
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
6. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
7. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
8. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
9. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... to Moorwick”: the adventures of a young Scottish girl yearning to see the world. ... mother of five who used her time waiting for children to finish their extracurricular activities ... It was a way to give some meaning to the hours I waited for ...
(Date:9/20/2017)... ... 2017 , ... “Monique”: is the story of Monique, whose mother’s deteriorating ... published author, Colleen Crispi, has owned four beauty salons and written a book regarding ... estate and cooking. , “The doctor’s office was only three blocks away, and ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading strategy, ... Flannery, to its strategic advisory and client development team. , In her ... clients across different industries to develop and implement market-justified strategies, modernize and transform ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , ... Innovation Awards (EIA), held this past Thursday night at The Space in Hamden. ... presented their innovative project ideas to a panel of judges for an opportunity ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology: